Zevra Therapeutics (ZVRA) Capital Expenditures (QoQ) (2014 - 2026)
Zevra Therapeutics (ZVRA) Capital Expenditures (QoQ) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn |
| 10 | Zevra Therapeutics | 564.79 Mn | 364.17 Mn | 34.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 212.90% |
| Dec 31, 2025 | -105.60% |
| Sep 30, 2025 | 160.09% |
| Jun 30, 2025 | 115.15% |
| Dec 31, 2023 | -58.14% |
| Sep 30, 2023 | 647.83% |
| Jun 30, 2023 | -20.69% |
| Mar 31, 2023 | 106.52% |
| Dec 31, 2022 | -1,689.29% |
| Sep 30, 2022 | -99.73% |
| Jun 30, 2022 | 200.30% |
| Mar 31, 2022 | -61,782.35% |
| Dec 31, 2021 | -73.02% |
| Sep 30, 2021 | 250.00% |
| Jun 30, 2021 | 350.00% |
| Mar 31, 2021 | -84.62% |
| Jun 30, 2020 | -25.00% |
| Mar 31, 2020 | -20.00% |
| Dec 31, 2019 | 25.00% |
| Mar 31, 2019 | 13.33% |